Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B

(2011) C. Negrier et al.   BLOOD

Haemophilia B: impact on patients and economic burden of disease

(2011) Thomas Thomson et al.   THROMBOSIS AND HAEMOSTASIS

Prolonged activity of factor IX as a monomeric Fc fusion protein

(2010) R. T. Peters et al.   BLOOD

Improvements in factor concentrates

(2010) David Lillicrap   CURRENT OPINION IN HEMATOLOGY

Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology

(2009) Chichi Huang   CURRENT OPINION IN BIOTECHNOLOGY

Fixed Dosing Versus Body Size-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials

(2009) Diane D. Wang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Half-life extension through albumin fusion technologies

(2009) Stefan Schulte   THROMBOSIS RESEARCH